user
menu
letter
Sign InRegister
langEnglisharrow

Mouse LY75 / CD205 Protein, His Tag (MALS verified)

Cat. No. / Size
Price
Availability
Qty
LY5-M52H5-100ug
$360.00
In Stock - Delivery in 1-2 business days
LY5-M52H5-1mg (250ug X 4)
$2,615.00
In Stock - Delivery in 2 weeks
LY5-M52H5
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
Request Quote
Product Details
Performance Data
Reviews & Citations
Resources
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

LY75, CD205, DEC-205, CLEC13B, Lymphocyte antigen 75, gp200-MR6

Source

Mouse LY75, His Tag (LY5-M52H5) is expressed from human 293 cells (HEK293). It contains AA Ser 28 - Asp 1667 (Accession # Q60767-1).

Predicted N-terminus: Ser 28

Molecular Characterization
Other Tags and Version Biotin & Other Labeled Version

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 190.0 kDa. The protein migrates as 230-260 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>90% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, 0.2 M Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System

Background

lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.